Form 4: Kyverna Therapeutics CFO Exercises Stock Options
SEC Form 4 Filing
Ryan Alexander Jones, CFO of Kyverna Therapeutics, exercised stock options to acquire shares of common stock at a price of $0.73 on May 28, 2024.
Summary
- On May 28, 2024, Ryan Alexander Jones, the Chief Financial Officer of Kyverna Therapeutics, exercised stock options.
- He acquired 10,870 shares of common stock at a price of $0.73 per share through one transaction.
- He acquired 7,146 shares of common stock at a price of $0.73 per share through another transaction.
- Following these transactions, Jones directly owns 43,950 shares of Kyverna Therapeutics common stock.
- The stock options were exercised pursuant to vesting schedules that began on April 15, 2021, and January 1, 2022.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to executive compensation and doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade in their company's stock. These filings provide transparency to the market.
Stakeholder Impact
- The transaction increases the CFO's stake in the company, aligning his interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/15/2021 | 25% of the original number of shares subject to one option vested, with subsequent monthly vesting. |
| 01/01/2022 | 25% of the original number of shares subject to another option vested, with subsequent monthly vesting. |
| 05/28/2024 | Date of the stock option exercises. |
| 05/29/2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.